Key Takeaways:
- Cresco Labs (CRLBF, Financial) reported a net loss of $15 million in Q1 and a 10.1% revenue decrease year-over-year.
- Analysts forecast significant potential upside with a target price of $3.00.
- The stock shows an "Outperform" rating based on brokerage recommendations.
Financial Overview of Cresco Labs' First Quarter
Cresco Labs (CRLBF), a prominent player in the cannabis industry, announced a challenging first quarter, registering a net loss of $15 million. The company recorded revenues of $165.76 million, representing a notable 10.1% decline compared to the same period last year. These results highlight the ongoing difficulties faced within the cannabis sector.
Analysts' Price Target and Future Outlook
Despite current hurdles, Cresco Labs holds promise according to analysts' forecasts. Based on one-year price targets from a single analyst, the average target price is set at $3.00, with both high and low estimates aligning at this figure. This predicts a potential upside of 342.74% from its existing price point of $0.68. For further insights, visit the Cresco Labs Inc (CRLBF, Financial) Forecast page.
Brokerage Recommendations and GF Value Estimate
In addition to positive price targets, Cresco Labs Inc's (CRLBF, Financial) stock carries an average brokerage recommendation of 2.1, categorizing it as "Outperform." This recommendation is based on a scale where 1 signifies a Strong Buy and 5 indicates a Sell, reflecting confidence from 8 brokerage firms.
Furthermore, GuruFocus estimates suggest a one-year GF Value for Cresco Labs Inc (CRLBF, Financial) of $1.41, indicating an upside of 108.09% from its current price of $0.6776. The GF Value is GuruFocus' assessment of the stock's fair trading value, considering historical trading multiples, past business growth, and future performance forecasts. Detailed data is accessible on the Cresco Labs Inc (CRLBF) Summary page.
